A B S T R A C T The results of studies in a patient with congenital deficiency of Factor XI who developed an inhibitor are presented. The patient presented with a severe, apparently spontaneous bleed into the thigh, which progressed despite infusion of fresh frozen plasma, but which responded promptly to activated prothrombin complex. During therapy with plasma his clotting time and Factor XI level were unresponsive and a Factor XI inhibitor titer of 6,000 U/ml was attained. The inhibitor was isolated and found to be polyclonal immunoglobulin G (IgG), predominantly of subclass 4. The specificity of the antibodies for Factor XI was shown by the ability of isolated inhibitor bound to polyacrylamide beads to remove Factor XI selectively from normal plasma. The binding of 125I-labeled factor XI to the inhibitor was studied and an affinity constant of 1.65 X 10"°liter/mol was found. Complexing of the antibodies with Factor XI was shown to block multiple activities of the clotting factor. Factor XI complexed with antibody did not bind to high molecular weight kininogen or undergo activation and cleavage by two-chain Factor XII. The complex of activated Factor XI with inhibitor prevented the cleavage and activation of Factor IX. Hence the inhibitor appears to act by binding to multiple sites on the Factor XI molecule and preventing its interaction with other molecules. Clinically these interactions of the inhibitor with Factor XI result in a state of severe Factor XI deficiency.
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The clinical circumstances of the case, with severe hemorrhage refractory to plasma infusion but readily responsive to an alternate clot-promoting agent, suggest that a defect of intrinsic system activation was critical, supporting the inference that Factor XI does participate in normal hemostasis. The clinical course of this patient, who has only had two documented hemorrhages in the presence of the inhibitor, is not as INTRODUCTION The occurrence of antibodies to specific coagulation factors presents both problems and opportunities. Practically, bleeding episodes often respond poorly to replacement therapy necessitating other approaches. From the theoretical point of view the antibody provides a new tool for exploring the biology of its antigen. Factor XI, which links the contact coagulation factors with the intrinsic system via Factor IX, has an ill-defined role in the physiology of hemostasis. We are aware of only one report of a patient with congenital Factor XI deficiency who developed an antibody to the factor (1) and of four other cases, which have not been reported (T. Spaet and R. Mibashan. Personal communication). Systemic lupus erythematosus with a circulating anticoagulant and low Factor XI level has been reported (2) . A patient seen by us with congenital deficiency of Factor XI and an acquired antibody presented with severe bleeding. The clinical manifestations of this patient and the properties of the antibody he developed are reported below. In 1975, the patient was readmitted for a right submandibular gland excision for chronic sialadenitis and removal of a sebaceous cyst of the back. Preoperative studies included PT = 12.7/11.2, aPTT = 180/62.9, thrombin time (TT) = 18.9/19, fibrinogen = 280 mg/dl, and bleeding time = 3'8" (nl < 7'). The factor XI level was <1%. Preoperatively, the patient received 10 U of fresh frozen plasma (FFP) and the Factor XI level had increased to 32%. 13 U of FFP were given over the first 3 (4)] was a gift of Dr. J. Koehn from Dr. R. E. Canfield's laboratory in the authors' department. All the above reagents were prepared from human plasma. Reagents obtained commercially were in all instances the highest quality available.
METHODS
Partial purification of inhibitor. The inhibitor was partially purified by sequential 40% ammonium sulfate precipitation, DEAE (A-50) Sephadex (5), protein A-Sepharose CL-4B (6), and Sephacryl S-200 chromatography (Pharmacia Fine Chemicals, Div. of Pharmacia Inc., Piscataway, NJ). The final product was characterized by immunodiffusion and sodium dodecyl sulfate polyacrylamide gels (SDS-PAGE). IgG was isolated in an identical manner from normal human pooled plasma and was free of Factor XI activity.
Preparation and use of immunoadsorbents. Normal rabbit serum and rabbit antisera to human immunoglobulins (heavy and light chains; N. L. Cappel Laboratories Inc., Cochranville, PA) were chromatographed on protein A-Sepharose CL-4B, and the eluted material (6) was coupled to CNBr-activated sepharose 4B (Pharmacia Fine Chemicals) following the manufacturer's directions (7) . Normal swine and rabbit antisera to human IgG heavy chain subclasses (Nordic Laboratories, El Toto, CA) were chromatographed on DEAE-affi-gel blue (Bio-Rad Laboratories, Richmond, CA) and the pass through fractions similarly pooled and coupled to CNBr-activated sepharose. After checking the adsorptive capacity (8) and specificity (9) of the columns, diluted patient plasma or partially purified inhibitor was (13) showed a single band of mol wt 160,000 unreduced and mol wt 80,000 reduced. 125I-Factor XI labeled by the chloramine T method retained full coagulant activity over the 1 wk it was used (stored at -70°C) and migrated identically to unlabeled material on SDS-PAGE.
Factor IX purified by the method of Kisiel and Davie (14) showed a single band reduced or unreduced of 55,000 mol wt on 10% SDS-PAGE with a sp act of 1,700 U/mg. Factor X coagulant activity was not detectable. '25I-Factor IX labeled by the chloramine T method as modified by Thompson (15) migrated identically to unlabeled material on SDS-PAGE and retained full clotting activity over the 1 wk it was used (stored at -70°C).
Binding studies. Binding of '251-Factor XI to the Factor XI inhibitor was determined as follows: 0.1 ml of dilutions of sample [in 0.01 M sodium phosphate (pH 7.5), 0.5 M sodium chloride, 1% bovine serum albumin (BSA)] and 0.1 ml of inhibitor plasma (10-5 dilution) was added to '251-Factor XI (104 cpm). After 16 h at 37°, 0.1 ml of IgGSorb (protein A bound to staphylococcus made by The Enzyme Center, Inc., Boston, MA) was added to each tube, and the tubes were incubated for 30 min (agitating every 3 min). 2 ml of buffer was added to each tube, which was then centrifuged at 3,500 rpm for 4 min. The supernatant was aspirated and the pellet counted. Assays were done in triplicate using siliconized tubes. '25I-Factor XI inhibitor binding reached equilibrium after 16 Specificity of binding. Specificity of binding was studied by adding samples to the above assay system. Activated clotting Factors (XIIa, XIa) were tested with and without prein-cubation for 90 min at 370C with diisopropylfluorosphate (DFP) (5 mM final concentration). Test solutions contained factors IX, X, XI, or fibrinogen (each 1 mg/ml and doubling dilutions), Factor XII (0.4 mg/ml and doubling dilutions), or buffer. Prekallikrein and high molecular weight kininogen were radiolabeled using the chloramine T method (16) . Both tracers retained coagulant activity. Binding studies using these tracers were performed as above and with longer incubation times (24 and 48 h), lower temperature (4°C, 230C), and lower ionic strength of the buffer (0.14 M or 0.08 M NaCl).
Effect of immobilized inhibitor on clotting tests of normal plasma. Citrated pooled plasma from normal volunteers, inhibitor plasma, purified control IgG, and inhibitor IgG (prepared as above) were coupled to polyacrylamide beads (Immunobead Matrix, Bio-Rad Laboratories) using 1- Coagulation assays. The Factor XI inhibitor was assayed by incubating equal volumes of inhibitor plasma and normal plasma for 1 h at 370C, and then assaying 0.1 ml of the mixture for Factor XI activity as described (20) . One inhibitor unit was defined as the amount of inhibitor required to activate 50% of Factor XI activity in 1 h at 370C as compared with the control.
In assays for Factors VIII, IX, X, XII, prekallikrein, and HMWK, the Factor XI-deficient plasma (George King Biochemical, Overland Park, KS) was replaced by the appropriate congenitally deficient plasma. The activated partial thromboplastin time and the prothrombin time were measured as described (20) .
RESULTS
Partial purification and immunological characterization of Factor XI inhibitor. Partially purified inhibitor eluted as a symmetrical peak from Sephacryl S-200 corresponding to a mol wt of 160,000. 7.5% SDS PAGE showed a single band of mol wt, 160,000, unreduced and two chains (mol wt 53,000 and 25,000) reduced. The inhibitory activity of unfractionated patient plasma had the same elution volume on Sephacryl S-200.
Immunoadsorption experiments using patient plasma and partially purified inhibitor2 demonstrated that the 2 Anti-a-immunoadsorption of purified inhibitor after the final gel filtration step was necessary to remove a small 5 Al of Factor XIa (2 Mg/ml) was preincubated with 5 ,ul of partially purified inhibitor at 370C followed by the addition of '25I-Factor IX (0.4 ,ug/ml) and 5 ,l of 50 mM CaC12. After 90 min at 370C the reaction was terminated with 10 Ml of 0.6 M EDTA, 18 Ml of 6% SDS and 5 Al of 2-mercaptoethanol. The sample was boiled, then 3 Ml of 0.05% bromphenol blue in 50% sucrose was added and 10 Ml applied to 10% SDS-PAGE.
inhibitor activity was entirely IgG. Both K and X immunoadsorbents-retained inhibitor activity was predominantly IgG4, but a small amount of inhibitor activity was retained on the IgG2 immunoadsorbent (Table I) . Immunodiffusion plates confirmed the presence of only y-heavy chain and both K and X-light chains in the partially purified preparation.
Binding curve and Scatchard Plot for 125I-Factor XI. The sigmoidal binding curve showed maximal (72-78% of the available counts) 1251-Factor XI binding by 10-2 to 10-4 dilution of inhibitor plasma and 50% tracer binding at 8 X 10-6 dilution (Fig. 2) (Table II) . The coagulant activity of Factors VIII, IX, XII, prekallikrein, high molecular weight kininogen, and the prothrombin time were not different in normal plasma exposed to beads coated with inhibitor or with normal whole plasma or partially purified IgG.
Effect of inhibitor on the cleavage of Factor IX by Factor IXa. Factor XIa cleaved 251I-Factor IX to form Factor IXa (mol wt 44,000) with heavy chain (mol wt 26,000), light chain (mol wt 18,000), and activation peptide (mol wt 12,000) (22) as clearly shown by SDS-PAGE of reduced protein (Fig. 4) . Preincubation of Factor XIa with the inhibitor completely prevented cleavage of 125I-Factor IX because the radioactivity profile was identical to that of '25I-Factor IX incubated with buffer. The results were comparable with celiteadsorbed activated contact product and all different dilutions of factor XIa. Control IgG had no effect on 125I-Factor IX cleavage.
Factor XIIa activation of Factor XI. Factor XIIa cleaved '251-Factor XI to form Factor XIa (mol wt 80,000) with heavy chain (mol wt 50,000) and light chain (mol wt 36,000) (11) shown on 10% SDS-PAGE along with the radioactivity profile of native '251-Factor XI (Fig. 5) . Preincubation of '25I-Factor XI with inhibitor prevented cleavage of Factor XI by Factor XIIa. Identical results were obtained when celite adsorbed activated contact product (or the different dilutions of Factor XIIa) was used. Control IgG had no effect of 125I-Factor XI activation.
HMWK Binding. '25I-Factor XI binds to HMWK immobilized on the surface of polypropylene tubes compared with albumin-coated controls. This binding was prevented by preincubation of '251-Factor XI with inhibitor but not purified control IgG (Fig. 6) . Preincubation of HMWK-coated plates with inhibitor, followed by washing and then incubation with '251-Factor XI had no effect on '25I-Factor XI HMWK binding. The antibody, therefore, prevents Factor XI HMWK complex formation by specifically combining with Factor XI.
DISCUSSION
The data shown in Table I indicate that the inhibitor present in this patient was a polyclonal IgG antibody mainly of heavy chain subclass 4. Evidence that the antibody was specific for Factor XI and no other coagulation factor is presented in Table II (23) (24) (25) . But this mechanism would suggest that Factor XI is not essential for hemostasis. It has been suggested that platelets can activate Factor XI directly bypassing Factor XII (26) (27) (28) , but this thesis is controversial (29) (30) . The rarity of a hemorrhagic diathesis in Factor XII deficiency (31) (32) 
